Back to results
US 2025/0074984 A1Published application
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
AssigneeSeismic Therapeutic, Inc.
InventorsYen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
Life of this patent
Estimating the term…
Abstract
Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
Claims22
An Fc polypeptide having at least 95% sequence identity to SEQ ID NO:
- 88, provided that the Fc polypeptide comprises a mutation set selected from:
- a mutation set of G237E and P238E, according to EU numbering;
- a mutation set of G237D, P238G, V240A, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L234F, L235E, P329A, H268D, and P271G, according to EU numbering;
- a mutation set of P238D, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of G237D, P238G, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of G237D, P238S, S239G, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L235V, P238E, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L235V, P238D, E269D, D270E, and A330R, and an insertion of an amino acid sequence GEV between positions 233 and 234, according to EU numbering;
- a mutation set of P238S, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L234F, L235E, S239D, P329A, H268D, and P271G, according to EU numbering;
- a mutation set of L234F and L235E, according to EU numbering;
- or
- any combination thereof.
11 more elements
2-5. (canceled)
8-9. (canceled)
The Fc polypeptide of claim 51, wherein the first Fc polypeptide comprises the amino acid sequence of:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, SEQ ID NO:
- 47, SEQ ID NO:
- 48, SEQ ID NO:
- 49, SEQ ID NO:
- 50, SEQ ID NO:
- 51, SEQ ID NO:
- 52, SEQ ID NO:
- 53, SEQ ID NO:
- 54, SEQ ID NO:
- 55, SEQ ID NO:
- 56, SEQ ID NO:
- 57, SEQ ID NO:
- 58, SEQ ID NO:
- 59, SEQ ID NO:
- 60, SEQ ID NO:
- 61, SEQ ID NO:
- 62, SEQ ID NO:
- 63, SEQ ID NO:
- 64, SEQ ID NO:
- 65, SEQ ID NO:
- 66, SEQ ID NO:
- 67, SEQ ID NO:
- 68, SEQ ID NO:
- 69, SEQ ID NO:
- 70, SEQ ID NO:
- 71, SEQ ID NO:
- 72, SEQ ID NO:
- 73, SEQ ID NO:
- 74, SEQ ID NO:
- 75, SEQ ID NO:
- 76, SEQ ID NO:
- 77, SEQ ID NO:
- 78, SEQ ID NO:
- 79, SEQ ID NO:
- 80, SEQ ID NO:
- 81, SEQ ID NO:
- 82, SEQ ID NO:
- 83, SEQ ID NO:
- 84, SEQ ID NO:
- 85, SEQ ID NO:
- 86, SEQ ID NO:
- 87, SEQ ID NO:
- 102, SEQ ID NO:
- 103, or SEQ ID NO:
- 104;
- and
- the second Fc polypeptide comprises the amino acid sequence of:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, SEQ ID NO:
- 47, SEQ ID NO:
- 48, SEQ ID NO:
- 49, SEQ ID NO:
- 50, SEQ ID NO:
- 51, SEQ ID NO:
- 52, SEQ ID NO:
- 53, SEQ ID NO:
- 54, SEQ ID NO:
- 55, SEQ ID NO:
- 56, SEQ ID NO:
- 57, SEQ ID NO:
- 58, SEQ ID NO:
- 59, SEQ ID NO:
- 60, SEQ ID NO:
- 61, SEQ ID NO:
- 62, SEQ ID NO:
- 63, SEQ ID NO:
- 64, SEQ ID NO:
- 65, SEQ ID NO:
- 66, SEQ ID NO:
- 67, SEQ ID NO:
- 68, SEQ ID NO:
- 69, SEQ ID NO:
- 70, SEQ ID NO:
- 71, SEQ ID NO:
- 72, SEQ ID NO:
- 73, SEQ ID NO:
- 74, SEQ ID NO:
- 75, SEQ ID NO:
- 76, SEQ ID NO:
- 77, SEQ ID NO:
- 78, SEQ ID NO:
- 79, SEQ ID NO:
- 80, SEQ ID NO:
- 81, SEQ ID NO:
- 82, SEQ ID NO:
- 83, SEQ ID NO:
- 84, SEQ ID NO:
- 85, SEQ ID NO:
- 86, SEQ ID NO:
- 87, SEQ ID NO:
- 102, SEQ ID NO:
- 103, or SEQ ID NO:
- 104,
- wherein the first Fc polypeptide and the second Fc polypeptide are the same or different.
182 more elements
15-41. (canceled)
A polypeptide comprising:
- an Fc polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:
- 88, provided that the Fc polypeptide comprises a mutation set selected from:
- a mutation set of G237E and P238E, according to EU numbering;
- a mutation set of G237D, P238G, V240A, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L234F, L235E, P329A, H268D, and P271G, according to EU numbering;
- a mutation set of P238D, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of G237D, P238G, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of G237D, P238S, S239G, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L235V, P238E, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L235V, P238D, E269D, D270E, and A330R, and an insertion of an amino acid sequence GEV between positions 233 and 234, according to EU numbering;
- a mutation set of P238S, E269D, D270E, and A330R, according to EU numbering;
- a mutation set of L234F, L235E, S239D, P329A, H268D, and P271G, according to EU numbering;
- a mutation set of L234F and L235E, according to EU numbering;
- or
- any combination thereof;
- an inhibitory receptor effector domain;
- and
- a FcγRII binding effector domain.
15 more elements
Dependencies are inferred from the claim text.